Last reviewed · How we verify
Dopamine Agonists
Dopamine agonists bind to and activate dopamine receptors in the brain, mimicking the effects of the neurotransmitter dopamine.
Dopamine agonists bind to and activate dopamine receptors in the brain, mimicking the effects of the neurotransmitter dopamine. Used for Parkinson's disease, Restless legs syndrome, Hyperprolactinemia.
At a glance
| Generic name | Dopamine Agonists |
|---|---|
| Also known as | Standard Care |
| Sponsor | Leiden University Medical Center |
| Drug class | Dopamine agonist |
| Target | Dopamine receptors (D1-D5) |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | FDA-approved |
Mechanism of action
Dopamine agonists are a class of drugs that directly stimulate dopamine receptors (D1, D2, D3, D4, or D5 subtypes) or increase dopamine availability in the central nervous system. By activating these receptors, they restore dopaminergic signaling in conditions where dopamine levels or receptor function are impaired, such as Parkinson's disease or hyperprolactinemia.
Approved indications
- Parkinson's disease
- Restless legs syndrome
- Hyperprolactinemia
- Pituitary adenoma (prolactin-secreting)
Common side effects
- Nausea
- Dizziness
- Orthostatic hypotension
- Hallucinations
- Somnolence
- Impulse control disorders
- Headache
Key clinical trials
- Efficacy of Cabergoline in Inhibiting Lactation and Alleviating Breast Symptoms (PHASE2)
- Randomized Placebo Controlled Trial Evaluating the Efficacy of Pimavanserin, a Selective Serotonin 5-HydroxyTryptamine-2A (5HT2A) Inverse Agonist, to Treat Impulse Control Disorders in Parkinson's Disease. (PHASE2)
- Intestinal Levodopa + Entacapone Therapy (Lecigon®) to Counteract Dopaminergic Desensitization and Neuropsychiatric Complications in Parkinson's Disease (PHASE3)
- A Study of Pasireotide in People With Prolactinoma (PHASE2)
- Carbergoline for Antipsychotic Induced Hyperprolactinemia. (PHASE4)
- Long Term Effectiveness of Levodopa-Entacapone-Carbidopa Intestinal Gel in Participants With Advanced Parkinson's Disease
- Long-Term Observational Study on Effectiveness and Safety of Lecigon in Patients With Advanced Parkinson's Disease
- Stanford RAD-AT Study (Research on Anxiety and Depression - Anhedonia Treatment)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dopamine Agonists CI brief — competitive landscape report
- Dopamine Agonists updates RSS · CI watch RSS
- Leiden University Medical Center portfolio CI